Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de estudo
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Molecules ; 28(14)2023 Jul 23.
Artigo em Inglês | MEDLINE | ID: mdl-37513467

RESUMO

Chitooligosaccharide (COS) is a natural product from the ocean, and while many studies have reported its important role in metabolic diseases, no study has systematically elaborated the anti-obesity effect and mechanism of COS. Herein, COSM (MW ≤ 3000 Da) was administered to diet-induced obese mice by oral gavage once daily for eight weeks. The results show that COSM administration reduced body weight; slowed weight gain; reduced serum Glu, insulin, NEFA, TC, TG, and LDL-C levels; increased serum HSL and HDL-C levels; improved inflammation; and reduced lipid droplet size in adipose tissue. Further lipidomic analysis of adipose tissue revealed that 31 lipid species are considered to be underlying lipid biomarkers in COS therapy. These lipids are mainly enriched in pathways involving insulin resistance, thermogenesis, cholesterol metabolism, glyceride metabolism and cyclic adenosine monophosphate (cAMP), which sheds light on the weight loss mechanism of COS. The Western blot assay demonstrated that COSM intervention can improve insulin resistance, inhibit de novo synthesis, and promote thermogenesis and ß-oxidation in mitochondria by the AMPK pathway, thereby alleviating high-fat diet-induced obesity. In short, our study can provide a more comprehensive direction for the application of COS in obesity based on molecular markers.


Assuntos
Resistência à Insulina , Camundongos , Animais , Camundongos Obesos , Lipidômica , Obesidade/tratamento farmacológico , Obesidade/etiologia , Obesidade/metabolismo , Metabolismo dos Lipídeos , Dieta Hiperlipídica/efeitos adversos , Lipídeos , Camundongos Endogâmicos C57BL , Proteínas Quinases Ativadas por AMP/metabolismo
2.
Eur J Clin Microbiol Infect Dis ; 38(11): 1987-1998, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31367997

RESUMO

The potential role of the gut microbiota in various human diseases has attracted considerable attention worldwide. Here, we discuss the vital role of the intestinal microbiota in the development of obesity. First, we describe how the gut microbiota promotes fat accumulation. Additionally, a high-fat diet leads to structural instability among in the gut microbiota, further leading to an increase in endotoxins, which aggravates obesity. We then discuss how gut microbiota metabolites, including short-chain fatty acids and lipopolysaccharides, affect the host. Finally, we review several strategies for regulating the intestinal flora.


Assuntos
Microbioma Gastrointestinal/fisiologia , Obesidade/microbiologia , Animais , Dieta Hiperlipídica/efeitos adversos , Disbiose/metabolismo , Disbiose/terapia , Endotoxinas/sangue , Endotoxinas/metabolismo , Ácidos Graxos Voláteis/metabolismo , Humanos , Inflamação/microbiologia , Lipopolissacarídeos/sangue , Lipopolissacarídeos/metabolismo , Obesidade/metabolismo , Obesidade/patologia , Obesidade/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA